Investments
15Portfolio Exits
3Funds
4Partners & Customers
2About Columbus Venture Partners
Columbus Venture Partner (CVP) is an independent venture capital that brings a unique approach for investing in outstanding early-stage and high growth opportunities in the life science industry in Spain. CVP portfolio is mainly invested in the Spanish market through its fund Columbus INNVIERTE Life Sciences FCR, in which the Spanish government participates through CDTI.
Columbus Venture Partners Headquarter Location
C/ Jose Abascal 58, 7D
Madrid, 28003,
Spain
Latest Columbus Venture Partners News
May 12, 2022
Artax Biopharma, a Cambridge, MA-based clinical stage biotechnology company, raised USD 26M in funding. The round was led by Eli Lilly and Company and Sound Bioventures with participation from Advent Life Sciences, Columbus Venture Partners, and Belinda Termeer and other shareholders.
Columbus Venture Partners Investments
15 Investments
Columbus Venture Partners has made 15 investments. Their latest investment was in Integra Therapeutics as part of their Seed VC - II on March 3, 2022.
Columbus Venture Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
3/29/2022 | Seed VC - II | Integra Therapeutics | $1.66M | Yes | 3 | |
1/3/2022 | Series C | Artax Biopharma | $26M | No | Advent Life Sciences, Belinda Termeer, Eli Lilly and Company, Sound Bioventures, and Undisclosed Investors | 3 |
7/7/2021 | Series B - II | NeRRe Therapeutics | $27.6M | Yes | 2 | |
3/22/2021 | Series E | |||||
2/4/2021 | Series D |
Date | 3/29/2022 | 1/3/2022 | 7/7/2021 | 3/22/2021 | 2/4/2021 |
|---|---|---|---|---|---|
Round | Seed VC - II | Series C | Series B - II | Series E | Series D |
Company | Integra Therapeutics | Artax Biopharma | NeRRe Therapeutics | ||
Amount | $1.66M | $26M | $27.6M | ||
New? | Yes | No | Yes | ||
Co-Investors | Advent Life Sciences, Belinda Termeer, Eli Lilly and Company, Sound Bioventures, and Undisclosed Investors | ||||
Sources | 3 | 3 | 2 |
Columbus Venture Partners Portfolio Exits
3 Portfolio Exits
Columbus Venture Partners has 3 portfolio exits. Their latest portfolio exit was Sanifit on November 22, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
11/22/2021 | Acquired | 6 | |||
Date | 11/22/2021 | ||
|---|---|---|---|
Exit | Acquired | ||
Companies | |||
Valuation | |||
Acquirer | |||
Sources | 6 |
Columbus Venture Partners Fund History
4 Fund Histories
Columbus Venture Partners has 4 funds, including Columbus Life Sciences Fund III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
|---|---|---|---|---|---|
4/26/2021 | Columbus Life Sciences Fund III | $144.99M | 2 | ||
9/23/2019 | Columbus Life Science Fund II | ||||
12/31/2016 | Columbus INNVIERTE Life Sciences | ||||
Columbus Venture Partners |
Closing Date | 4/26/2021 | 9/23/2019 | 12/31/2016 | |
|---|---|---|---|---|
Fund | Columbus Life Sciences Fund III | Columbus Life Science Fund II | Columbus INNVIERTE Life Sciences | Columbus Venture Partners |
Fund Type | ||||
Status | ||||
Amount | $144.99M | |||
Sources | 2 |
Columbus Venture Partners Partners & Customers
2 Partners and customers
Columbus Venture Partners has 2 strategic partners and customers. Columbus Venture Partners recently partnered with AskBio on October 10, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
10/17/2017 | Partner | United States | AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen Asklepios BioPharmaceutical , Inc. announced today the formation of Viralgen , a gene therapy joint venture with Columbus Venture Partners . | 2 | |
10/17/2017 | Partner |
Date | 10/17/2017 | 10/17/2017 |
|---|---|---|
Type | Partner | Partner |
Business Partner | ||
Country | United States | |
News Snippet | AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen Asklepios BioPharmaceutical , Inc. announced today the formation of Viralgen , a gene therapy joint venture with Columbus Venture Partners . | |
Sources | 2 |
Columbus Venture Partners Team
3 Team Members
Columbus Venture Partners has 3 team members, including current President, General Partner, Javier G Cogorro.
Name | Work History | Title | Status |
|---|---|---|---|
Javier Garcia | Founder | Current | |
Javier G Cogorro | President, General Partner | Current | |
Victor Vercher | Chief Financial Officer | Former |
Name | Javier Garcia | Javier G Cogorro | Victor Vercher |
|---|---|---|---|
Work History | |||
Title | Founder | President, General Partner | Chief Financial Officer |
Status | Current | Current | Former |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.